Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Impact of Racial, Age, Marital, and Socioeconomic Status Disparities on the Survival of Hairy Cell Leukemia: A Population-Based Study

Neveen Mostafa, Mohamed Ahmed, Yousra Alghalban, Daniel Lebovic, Zyad Kafri

Blood (2023) 142 (Supplement 1): 2419.

https://doi.org/10.1182/blood-2023-182869

Published: 2023

Journal Articles

Prevalence of Iron Deficiency in Endurance Runners: A Cross-Sectional Study of the Detroit Free Press Marathon and Half-Marathon Athletes

Laura Kohler, Zachary Pounders, Aditi Singh, Rida Jamal, Zeyad Sako, Adrian Tsui, Joseph Attallah, Daniel Lebovic, Zyad Kafri, Carrie Lynn Dul, Hosam Hakim, Jeffrey Lei

Blood (2022) 140 (Supplement 1): 11074–11075.

https://doi.org/10.1182/blood-2022-160151

Published: 2022

Journal Articles

A Prospective Study Evaluating the Serological Profile of the Novel Coronavirus (COVID-19) Vaccines in Cancer Patients

Aditi Singh, Hemang Patel, Ahmed Abdalla, Talal Bazzi, Mohamed Issa, Hussein Gharib, Laura Kohler, Natali Salaytah, Nilamben Mangukia, Hosam Hakim, Carrie Lynn Dul, Zyad Kafri, Susan Szpunar, Daniel Lebovic, Louis Saravolatz

Blood (2022) 140 (Supplement 1): 5502–5503.

https://doi.org/10.1182/blood-2022-160414

Published: 2022

Journal Articles

Clinical and Immunological Assessment of Patients with Sars-Cov-2 Infections

Aditi Singh, Natali Salaytah, Daniel Lebovic, Zeyad Sako, Zachary Pounders, Laura Kohler, Zyad Kafri, Louis Saravolatz, Meredith Coyle, Hemang Patel

Blood (2021) 138 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2021-154024

Published: 2021

Journal Articles

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

Blood (2015) 126 (23): 5322.

https://doi.org/10.1182/blood.V126.23.5322.5322

Published: 2015

Journal Articles

Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study

Cara A. Rosenbaum, MD, Vishal Kukreti, MD, Jeffrey Zonder, MD, Daniel Lebovic, MD, Todd Zimmerman, MD, Jesus G. Berdeja, MD, Kathryn McDonnell, BS, Jessica Waite-Marin, MS, PA-C, Kent A. Griffith, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2109.

https://doi.org/10.1182/blood.V124.21.2109.2109

Published: 2014

Journal Articles

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Jagoda Jasielec, Dominik Dytfeld, Kent A. Griffith, Kathryn McDonnell, Daniel Lebovic, Malathi Kandarpa, PhD, Tara Anderson, Melissa Mietzel, Malek Faham, Liana Lee, Joan Levy, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark Kaminski, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2127.

https://doi.org/10.1182/blood.V124.21.2127.2127

Published: 2014

Journal Articles

Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma

Marc S Raab, MD PhD, Enrique M Ocio, Sheeba K. Thomas, MD, Andreas Günther, MD, Yeow-Tee Goh, MBBS,MMed, Daniel Lebovic, MD, Andrzej Jakubowiak, MD PhD, Dongweon Song, F Xiang, Apurva Patel, K. Gary Vanasse, MD, Shaji Kumar, MD

Blood (2014) 124 (21): 301.

https://doi.org/10.1182/blood.V124.21.301.301

Published: 2014

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Blood (2014) 124 (21): 291.

https://doi.org/10.1182/blood.V124.21.291.291

Published: 2014

Journal Articles

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

Hongxiu Li, Mark S. Kaminski, Yifeng Li, Mehmet Yildiz, Peter Ouillette, Siân Jones, Heather Fox, Kathryn Jacobi, Kamlai Saiya-Cork, Dale Bixby, Daniel Lebovic, Diane Roulston, Kerby Shedden, Michael Sabel, Lawrence Marentette, Vincent Cimmino, Alfred E. Chang, Sami N. Malek

Blood (2014) 123 (10): 1487–1498.

https://doi.org/10.1182/blood-2013-05-500264

Published: 2014

Includes: Supplemental data

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Ranjana Advani, MD, Andy I. Chen, MD, PhD, Daniel Lebovic, MD, Mark W. Brunvand, MD, Andre Goy, MD, Julie E. Chang, MD, Ephraim Hochberg, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 4399.

https://doi.org/10.1182/blood.V122.21.4399.4399

Published: 2013

Journal Articles

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Erik H van Beers, PhD, Martin H. Van Vliet, PhD, Kenneth C. Anderson, MD, Ajai Chari, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Shaji K Kumar, MD, Daniel Lebovic, MD, Joan Levy, PhD, Sagar Lonial, M.D., Donna E Reece, MD, FRCPC, Paul G. Richardson, MD, David S Siegel, MD, PhD, Keith Stewart, MBA, MB, CHB, Suzanne Trudel, MD, MSC, FRCPC, Ravi Vij, MD, Todd M. Zimmerman, MD, Rafael Fonseca, M.D.

Blood (2013) 122 (21): 1854.

https://doi.org/10.1182/blood.V122.21.1854.1854

Published: 2013

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

Journal Articles

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

Marc S Raab, MD, Enrique M. Ocio, Sheeba K. Thomas, M.D., Andreas Günther, Daniel Lebovic, MD, Shaji K Kumar, MD, Andrzej J. Jakubowiak, MD, PhD, Dongweon Song, Fang Xiang, David Hynds, K. Gary Vanasse, M.D., Yeow Tee Goh, MD

Blood (2013) 122 (21): 3186.

https://doi.org/10.1182/blood.V122.21.3186.3186

Published: 2013

Journal Articles

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Paul G. Richardson, MD, Craig C Hofmeister, MD, Cara A Rosenbaum, MD, Myo Htut, MD, David H. Vesole, MD, PhD, Jesus Berdeja, MD, Michaela Liedtke, MD, Ajai Chari, MD, Stephen D Smith, MD, Daniel Lebovic, MD, Deborah Berg, RN, MSN, Eileen Liao, Ph.D, Neeraj Gupta, Ph.D, Alessandra Di Bacco, Ph.D, Jose Estevam, BS, MS, Ai-Min Hui, Rachid Baz, MD

Blood (2013) 122 (21): 535.

https://doi.org/10.1182/blood.V122.21.535.535

Published: 2013

Journal Articles

Recurrent STAT6 Mutations In Follicular Lymphoma

Sami Malek, MD, Mark S. Kaminski, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, PA-C, Kathryn Jacobi, NP, Kamlai Saiya-Cork, Dale Bixby, MD, PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mehmet Yildiz, MD

Blood (2013) 122 (21): 503.

https://doi.org/10.1182/blood.V122.21.503.503

Published: 2013

Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Suzanne Trudel, MD, P. Leif Bergsagel, MD, Seema Singhal, M.D., Ruben Niesvizky, MD, Raymond L. Comenzo, MD, William I. Bensinger, MD, Daniel Lebovic, MD, YounJeong Choi, Dan Lu, Dorothy French, Elicia Penuel, William Ho, MD, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4029.

https://doi.org/10.1182/blood.V120.21.4029.4029

Published: 2012

Journal Articles

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ranjana Advani, MD, Daniel Lebovic, MD, Mark Brunvand, MD, Andy I. Chen, MD, PhD, Andre Goy, MD, Julie E. Chang, MD, Lauren S Maeda, MD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Bruce D. Cheson, MD

Blood (2012) 120 (21): 59.

https://doi.org/10.1182/blood.V120.21.59.59

Published: 2012

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 1636.

https://doi.org/10.1182/blood.V120.21.1636.1636

Published: 2012

NARROW

Impact of Racial, Age, Marital, and Socioeconomic Status Disparities on the Survival of Hairy Cell Leukemia: A Population-Based Study

Prevalence of Iron Deficiency in Endurance Runners: A Cross-Sectional Study of the Detroit Free Press Marathon and Half-Marathon Athletes

A Prospective Study Evaluating the Serological Profile of the Novel Coronavirus (COVID-19) Vaccines in Cancer Patients

Clinical and Immunological Assessment of Patients with Sars-Cov-2 Infections

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Recurrent STAT6 Mutations In Follicular Lymphoma

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only